Yale registers Gaucher natural history study with Sanofi collaboration
New observational trial tracks neuronopathic, skeletal, and Parkinson-overlap Gaucher disease under standard-of-care therapy.
This week's notable registry item is a new Yale-led observational study on Gaucher disease.
- A new observational study, "Advancing Integrated Therapies for Gaucher Disease" (NCT07758816), is recruiting to study natural history, clinical outcomes, and biological features of Gaucher disease in patients receiving standard medical care.1 The study is sponsored by Yale University with Sanofi-Yale External Research Collaboration1 as collaborator, and plans to enroll 30 participants (estimated).1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.